Department of Family Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
School of Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan.
Expert Rev Anti Infect Ther. 2021 Aug;19(8):1039-1046. doi: 10.1080/14787210.2021.1878025. Epub 2021 Mar 1.
The study was to compare the efficacy between IV peramivir and oral oseltamivir treatments in patients with influenza.
The PubMed, EMBASE, Scopus, ClinicalTrials.gov, and Cochrane Library databases were searched for studies published before January 2020.
The meta-analysis was conducted to calculate the pooled effect size by using a random-effects model. Seven randomized controlled trials (RCTs) including 1,138 patients were reviewed. The incidence of total complications revealed no significant difference between 600 mg IV peramivir (P600) and 75 mg oral oseltamivir (O75) treatments (2.8% vs. 4.1%; risk ratio [RR] = 0.70; 95% confidence interval [CI]: 0.36-1.38). The incidence of pneumonia was not significantly different between the P600 and O75 treatment groups (2.2% vs. 2.7%; RR = 0.74; 95% CI: 0.37-1.51). Regarding the time to the alleviation of symptoms, no difference was found in P600 and O75 treatment (MD = -3.00; 95% CI: -11.07 to 5.06). The rate of fever clearance in 24 h and the time to fever resolution were not statistically different between the IV peramivir and oral oseltamivir treatments (at different dosages) groups.
The treatment of influenza with IV peramivir or oral oseltamivir had similar clinical efficacy.
本研究旨在比较静脉滴注帕拉米韦和口服奥司他韦治疗流感的疗效。
检索 PubMed、EMBASE、Scopus、ClinicalTrials.gov 和 Cochrane Library 数据库，查找截至 2020 年 1 月发表的研究。
采用随机效应模型计算合并效应量进行荟萃分析。共纳入 7 项随机对照试验（RCT），共 1138 例患者。总并发症发生率方面，600 mg 静脉滴注帕拉米韦（P600）与 75 mg 口服奥司他韦（O75）治疗组无显著差异（2.8%比 4.1%；风险比[RR] 0.70；95%置信区间[CI]：0.361.38）。肺炎发生率方面，P600 与 O75 治疗组也无显著差异（2.2%比 2.7%；RR 0.74；95%CI：0.371.51）。症状缓解时间方面，P600 与 O75 治疗组也无差异（MD=-3.00；95%CI：-11.07~5.06）。24 h 内退热率及退热时间在不同剂量静脉滴注帕拉米韦和口服奥司他韦治疗组之间也无统计学差异。
静脉滴注帕拉米韦或口服奥司他韦治疗流感的临床疗效相当。
